February 4, 2025 – Plymouth, MA – MitoSense Inc., a pioneering biotechnology company
specializing in mitochondria-based therapeutics, is proud to announce that it has been granted a
Japanese patent (Patent No. 7617652) for its innovative approach to treating neurodegenerative
diseases, including Amyotrophic Lateral Sclerosis (ALS). This milestone underscores
MitoSense’s commitment to revolutionizing medical treatments for neurodegenerative disorders
through its proprietary Mitochondria Organelle Transplantation (MOT™) technology.
The newly granted Japanese patent, titled "Compositions and Methods for the Treatment of ALS
and Other Neurodegenerative Diseases," covers the company’s cutting-edge methodology of
isolating and transplanting healthy mitochondria from donor cells into patients suffering from
mitochondrial dysfunction. This breakthrough therapy aims to restore cellular energy production
and mitigate disease progression, offering a novel and potentially transformative treatment for
patients worldwide.
"Securing this patent in Japan represents a significant step forward for MitoSense as we continue
to expand the global reach of our proprietary MOT technology," said Van Hipp, Chairman of
MitoSense. "With neurodegenerative diseases affecting over 55 million people worldwide,
including approximately 200,000 individuals suffering from ALS globally, our innovative
approach has the potential to change lives by addressing mitochondrial dysfunction at its core."
The Japanese patent builds upon MitoSense’s growing intellectual property portfolio,
complementing its recently secured U.S. patent for the same technology. As a leader in
mitochondrial research and therapeutics, MitoSense continues to advance clinical development
and strategic partnerships to bring this groundbreaking treatment to patients in need.
With this patent protection, MitoSense is poised to explore collaborations with leading Japanese
research institutions and pharmaceutical companies to accelerate the clinical application of its
mitochondrial transplantation technology in the region. This milestone strengthens MitoSense’s
position as an innovator in regenerative medicine and underscores the company’s commitment to
developing novel therapies for neurodegenerative diseases.
For more information on MitoSense Inc. and its groundbreaking research, please visit
www.mitosense.com.
About MitoSense Inc. MitoSense Inc. is a biotechnology company at the forefront of
mitochondrial research, developing revolutionary treatments for neurodegenerative and
metabolic disorders. The company’s Mitochondria Organelle Transplantation™ (MOT™)
technology aims to restore cellular function by introducing healthy mitochondria into
compromised cells, offering a promising new avenue for treating diseases linked to
mitochondrial dysfunction.